Systemic therapies for breast cancer, including anti-estrogen therapies, anti-Her2 therapies, and chemotherapy, are selected based upon tumor subtype (i.e., estrogen receptor and Her2 status), tumor stage, lymph node status, and other biological features relevant to risk stratification. Here, ERBB2 is linked to neoplasm.